Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02063958
Title Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Esanex Inc.
Indications

neuroendocrine tumor

Therapies

SNX-5422

Age Groups: adult
Covered Countries USA


No variant requirements are available.